Oral solid lipid nanoparticle-based antitubercular chemotherapy

Pandey, Rajesh; Sharma, Sonal; Khuller, G. K.

doi:10.1016/j.tube.2005.08.009

Cited by 239 publications

(95 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is noteworthy that the solid lipid nanoparticles display important advantages, such as the composition (physiologic compounds) and the possibility of large-scale production favored by the feasibility to avoid organic solvents in the manufacturing process [78]. A sterilizing effect was achieved after administration of solid lipid nanoparticles [79]. No tubercle bacilli could be detected in the lungs/spleen after seven doses of treatment of infected guinea pigs with drugloaded solid lipid nanoparticles.…”

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

“…In M. tuberculosis H37Rv infected mice, 5 oral doses at every 10 th day of drug loaded SLNs were sufficient to completely suppress bacterial load in the lungs/spleen whereas free drug required administration of 46 daily oral doses to get same effect. SLN incorporated antitubercular drug significantly reduced the dosing frequency and improved bioavailability [79]. Nanosuspensions Nanosuspensions, poor water soluble drugs are dispersed in aqueous phase containing stabilizing agent.…”

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

See 1 more Smart Citation

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

-Nanotechnology has offered enormous improvement in field of therapeutics by means of designing of drug delivery systems and opened the possibility of controlling infections at the molecular level. Nanocarriers can cross biological barriers and are able to target cellular reservoirs of Mycobacterium tuberculosis (M. tuberculosis). Nanoparticle-based systems have significant potential for treatment and prevention of tuberculosis (TB). A variety of nanocarriers have been widely evaluated as potential drug delivery systems for various administration routes. Targeting the drugs to certain physiological sites such as the lymph nodes has emerged as a promising strategy in treating TB with improved drug bioavailability and reduction of the dosing frequency. Nanotechnology based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimes, ultimately resulting in more patients compliance and thus attain higher adherence levels. The development of nanoparticle based aerosol vaccine is undergoing which could serve as new platform for immunization. Present article compiles the general physiological aspects of the infection along with new research uptades on nanocarriers used in prevention of tuberculosis. _______________________________________________________________________________________

show abstract

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

Section: Solid Lipid Nanoparticles (Sln)mentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

show abstract

“…Complete clearance of MTB infection was observed in infected lung and splenic tissues after a mere 10 d course of treatment. [34] Taken together, these results provide convincing evidence for the utility of nanoparticles as enhanced drug delivery systems for anti-TB treatment. Nanoparticles hold great promise for improved drug targeting, greater in vivo therapeutic efficacy and reduced drug toxicity.…”

Section: Polymer Nanoparticles As Anti-tb Drug Delivery Carriersmentioning

confidence: 64%

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections

Liang

Ding

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

worldwide was estimated at a staggering 10.4 million, with a significant percentage (10%) resulting from concomitant HIV-TB coinfections. [1] Given the closely knitted association between TB infections and poor sanitation/poverty, it thus comes with no surprise that an overwhelming majority of disease burden (60%) is actually shouldered by countries from the developing world (Figure 1). [1] TB infections are compounded by the emergence of multidrug resistance (MDR). In spite of the tremendous amount of resources and research dollars that have been devoted to TB research, TB diagnostics and treatment outcomes still remain startlingly poor. TB remains worryingly underreported, under-diagnosed and undertreated. A 4.3 million gap was reported between incident and notified TB cases, chiefly in developing countries; majority of TB infections remain latent and unreported, and only 30% of new incident TB cases were subjected to drug susceptibility testing. [1] The Xpert Mycobacterium Tuberculosis (MTB)/RIF assay remains the only available WHOrecommended rapid diagnostic platform for detection of TB and drug (rifampicin) resistance. Treatment success rates are highly variable, ranging from 28% (extensively drug-resistant strains) to 83% (garden strains) of TB. The rate of decline in TB incidence has remained stagnant at 1.5% annually over the past decade, far lagging behind the 5% projected by the WHO's End TB Strategy. Against such a backdrop, TB remains firmly entrenched among the top 10 causes of death worldwide. [2] To this end, the WHO has since 2015, adopted the End TB Strategy in an effort to stem this burgeoning epidemic. Major diagnostic and treatment gaps in TB management still remain, and these need to be addressed to effectively curtail TB spread and its impact on global health. Pathogenesis of TB InfectionsMTB is the infectious agent responsible for TB infections. It originates from the family Mycobacteriaceae and is an obligate bacteria chiefly spread via air droplets.

show abstract

“…In the context of anti-tubercular therapy, solid lipid nanoparticles based on stearic acid (Figure 1) and prepared by emulsion solvent diffusion were loaded with rifampicin, isoniazid and pyrazinamide, and administered by both the oral (Pandey et al, 2005) and the pulmonary route (Pandey and Khuller, 2005b) to Mycobacterium tuberculosisinfected mice and guinea pigs, respectively. After oral administration, therapeutic drug levels were detected in plasma for 8 days and in tissues (lung, spleen, liver) for 10 days.…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%